Abbott's MDx Sales Fall 8 Percent in Q3 as Total Revenues Decline Slightly | GenomeWeb

NEW YORK (GenomeWeb News) – Abbott today reported that its third-quarter revenues declined a fraction of one percent to $9.77 billion from $9.82 billion as the firm nears its planned split into two separate, publicly-traded companies.

It fell short of Wall Street's consensus estimate for revenues of $9.94 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.